BCMA Drug Prices For Multiple Myeloma Don't Match Their Benefit, ICER Concludes

BMS And J&J CAR-Ts, And GSK's ADC Were Reviewed By ICER

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.